On August 2, "NorthGrid," the portfolio company invested in by Jifeng Capital— a sub-fund backed by the mother fund managed by Yuanhe Chencun—officially listed on the ChiNext Board of the Shenzhen Stock Exchange, with stock code: 301333.

Founded in 2008, Northway is a leading, large-scale clinical trial outsourcing service provider in China. It has established a comprehensive pharmaceutical R&D outsourcing service system, offering sponsors integrated, end-to-end solutions for the entire drug clinical development process—and boasts full-service capabilities spanning the entire clinical trial value chain. Over more than a decade of growth in the clinical CRO sector, Northway has assembled a team of expert scientists capable of delivering top-level strategic design for clinical trials, with its workforce now exceeding 1,800 professionals.

Northway's core business encompasses clinical trial operations services, on-site clinical trial management services, bio-sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services. As one of the largest clinical trial outsourcing service providers in China, Northway has established strategic partnerships with numerous pharmaceutical companies and clinical research institutions. To date, it has collaborated with over 790 medical institutions nationwide and delivered high-quality, efficient, and internationally or domestically compliant clinical trial outsourcing services to more than 750 clients—both domestic and international—accumulating expertise across more than 3,300 diverse projects.

The company has served clients that include several pharmaceutical enterprises listed in the 2019 "Top 100 Chinese Pharmaceutical Companies" ranking released by the China Association of Industry and Commerce for the Pharmaceutical Industry, as well as multiple globally leading multinational pharmaceutical firms and innovative drug companies listed domestically or abroad. Additionally, the company has supported sponsors in participating in the research and development of several major national projects spanning diverse therapeutic areas such as oncology, cardiovascular diseases, endocrinology, respiratory health, mental health, neurology, gastroenterology, immunology, hematology, and urology.

Taking this ChiNext listing as an opportunity, Northway will deepen its focus on existing businesses, strengthen its industry position, and further enhance the brand’s recognition and influence across China. Looking ahead, the company will continuously refine its management practices, foster ongoing innovation, and expand both its business regions and scope—aiming to build Northway into a globally competitive, world-class CRO enterprise.